On 27 August 2020, the CMA applied for a director disqualification order against Mr. Pritesh Sonpal in connection with its decision to fine the company of which he is a director, Lexon, for exchanging commercially sensitive information about Nortriptyline Tablets with two other companies. On 17 September 2020, the High Court published an Order transferring the question of whether Lexon had committed a breach of competition law to the CAT. If the CAT decides Lexon has committed a relevant breach of competition law, the High Court will then have to consider whether Mr. Sonpal’s conduct in connection with that breach makes him unfit to be involved in the management of a company pursuant to section 9A of the Company Directors Disqualification Act 1986. Lexon has separately launched an appeal in the CAT against the fine that the CMA imposed. As part of the appeal, Lexon is challenging the CMA’s classification of the infringement as a ‘by object’ infringement, the finding that it committed a single continuous infringement, and the level of the fine imposed. The hearings for the appeal and director disqualification action are scheduled to be held together from 16 November 2020 for five and a half days.